読み込み中
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
通常取引
$0.772
+$0.002 · +0.26%
日中の時刻はETです。市場データは遅延する場合があります。
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
日中レンジ
現在 $0.772
52週レンジ
現在 $0.772
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
25
割高
センチメント
47
まちまち
リスク
66
高リスク
モメンタム
20
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
日中レンジ
現在 $0.772
52週レンジ
現在 $0.772
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 38.9万 USD | — | — | — |
| 粗利益 | — | −38.9万 USD | — | — | — |
| 研究開発 | 1260.6万 USD | 2847.6万 USD | 1749.8万 USD | 2252.7万 USD | 1716.6万 USD |
| 販売・一般管理 | 1396.9万 USD | 1355万 USD | 1165.9万 USD | 1211.3万 USD | 982万 USD |
| 営業費用 | 2657.5万 USD | 4163.7万 USD | 2915.7万 USD | 3464万 USD | 2698.6万 USD |
| 受取利息 | 52万 USD | 149.9万 USD | 111.5万 USD | 54.9万 USD | 1282 USD |
| 支払利息 | 20.7万 USD | 131.6万 USD | 144.9万 USD | 161.8万 USD | 128.2万 USD |
| 減価償却費と償却費 | 26.6万 USD | 38.9万 USD | 38.1万 USD | 63.8万 USD | 37.4万 USD |
| 営業利益 | −2657.5万 USD | −4202.6万 USD | −2915.7万 USD | −3464万 USD | −2698.6万 USD |
| 純利益 | −2626.2万 USD | −4184.3万 USD | −2949.1万 USD | −3570.9万 USD | −2830.2万 USD |
会社概要が更新されました 2026年10月9日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年4月9日 | 1:13 | — | — |
株式分割 | 2021年6月28日 | 1:15 | — | — |
株式分割 | 2018年12月10日 | 1:15 | — | — |
発効済み 2025年4月9日
1:13
発効済み 2021年6月28日
1:15
発効済み 2018年12月10日
1:15
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
